ArticleJACC. Case reports2026
3 Discordant Extracardiac Amyloid Proteins Highlighting Bystander Deposition in a Case of Light-Chain Amyloid Cardiomyopathy.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate differentiation of immunoglobulin light-chain (AL) from transthyretin (ATTR) amyloid cardiomyopathy is critical, as misclassification may delay appropriate therapy and worsen outcomes. CASE SUMMARY: An 80-year-old woman with incidental gallbladder AL lambda and ApoA-IV amyloid deposits had elevated cardiac biomarkers and lambda monoclonal gammopathy. Bone marrow biopsy demonstrated AL and ATTR deposits. Echocardiography showed increased wall thickness, apical-sparing strain, and elevated filling pressures. Given these discordant findings, endomyocardial biopsy (EMB) was performed; proteomic analysis confirmed AL lambda deposition without ATTR, prompting anti-plasma cell therapy. DISCUSSION: This is a rare case of mixed extracardiac amyloid required EMB with proteomic analysis to resolve discordant findings and confirm AL cardiomyopathy. TAKE-HOME MESSAGES: Amyloid cardiomyopathy subtyping is essential because AL and ATTR amyloidosis treatment differ fundamentally. Underrecognized codeposited "bystander" proteins may confound typing; therefore, discordant extracardiac findings may not represent the myocardial subtype. When uncertainty persists, particularly with monoclonal gammopathy, EMB is essential to define cardiac amyloid subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.